Deep Dive Moving from autologous to allogeneic ACT paradigms We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT).
Oncology Liver cancer diagnostic gets FDA breakthrough status, with P... Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
